Full support for the fight against the new coronavirus (COVID-19) ,SANLI MEIDCAL successfully developed a Virus specimen collection tube (Non-frozen type)!

At the beginning of the new coronavirus (COVID-19) outbreak, Liuyang SANLI Medical Technology Development Co., Ltd. organized a team to develop the Virus specimen collection tube needed to detect the new coronavirus (COVID-19) during the Spring Festival. The specimen tube was developed in only 10 days, greatly improving The speed of new coronavirus (COVID-19) detection.

SANLI Medical was established in 1991 and specializes in Vacuum Blood Collection Tubes and Blood Collection Needles. SANLI (Vaculab®）is the first Chinese brand for vacuum blood collection system to enter the Chinese market. In the past 29 years, SANLI Medical has been continuously focusing on the technology development and products quality improvement.

On the second day of the Chinese new year, just before the outbreak of the new coronavirus (COVID-19) outbreak, Liuyang SANLI Medical Technology Development Co., Ltd. was appointed by Hunan Province as a key contact company for the prevention and control of the new coronavirus (COVID-19). The company’s R & D technicians and team learned that the market urgently needed a virus specimen collection tube, so they took the initiative to ask for it, give up the rest, and invested in the development of the virus specimen collection tube, consulting the information and formulating the plan. However, the research and development process didn’t go smoothly, and the results prepared by the technical team differed greatly from the original formula. To this end, the company’s technical team, regardless of day and night, after several comparisons of raw materials, adjustment plans, and verification experiments, finally successfully developed this product on February 10, and actively assisted the production department to achieve mass production. The company on February 15, 2020 has made a record of a class of medical devices for this product in Changsha Market Supervision Administration. The company’s technology spreads protection knowledge in the company’s WeChat group to employees who are about to resume work every day, so that virus specimen collection tube can be mass-produced in the shortest time.

During this period, the Jili Sub-district Office where the company was located learned of the company’s resumption of work and immediately coordinated the relevant departments. After receiving the application for resumption of work, the District Commerce Committee urgently handled the matter, and completed the relevant procedures for the resumption of work within 1 day, so that after the medical device was filed, the company could immediately start production. The Jili Sub-district Office also sent someone to contact the enterprise to help the company grasp the epidemic prevention and resume production again, and also help the enterprise apply for the relevant rewards in the special time.

Virus specimen collection tube are the main products for detecting new coronavirus (COVID-19). Since the outbreak, the demand for Virus specimen collection tube has been increasing, and orders from medical institutions in Shanghai and the Yangtze River Delta have been endless. Because some upstream companies did not fully resume to work, the raw materials were not able to keep up with the moment. There were only 4,000 Virus specimen collection tube in the company’s daily production, and under normal circumstances, the company could produce more than 40,000 Virus specimen collection tube per day. In order to speed up the production progress, the company uses various relationships to contact upstream companies to find raw material producers.

With the successive resumption of work by enterprises in various places, the situation of inadequate supply of raw materials will gradually ease, and Liuyang SANLI Medical Technology Development Co., Ltd.’s virus specimen collection tube will also return to daily levels and is currently operating at full capacity. The company’s R & D technical team is currently accelerating the development of second-generation virus sampling tubes to suit different populations and meet clinical needs.

“To be the leader of Vacuum Blood Collection System industry around the world” is our development goal. SANLI Medical would keep goal, and make efforts to contribute to the human health in all parts of the world.

Containment of new coronavirus (COVID-19) must be a top priority for all countries. Let us fight the virus together and achieve a final victory at an early date.